Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans

Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans

Abstract Background Parkinson’s disease is a disabling neurodegenerative movement disorder characterized by dopaminergic neuron loss induced by α-synuclein oligomers. There is an urgent need for disease-modifying therapies for Parkinson’s disease, but drug discovery is challenged by lack of in vivo...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kevin S. Chen, Krystal Menezes, Jarlath B. Rodgers, Darren M. O’Hara, Nhat Tran, Kazuko Fujisawa, Seiya Ishikura, Shahin Khodaei, Hien Chau, Anna Cranston, Minesh Kapadia, Grishma Pawar, Susan Ping, Aldis Krizus, Alix Lacoste, Scott Spangler, Naomi P. Visanji, Connie Marras, Nour K. Majbour, Omar M. A. El-Agnaf, Andres M. Lozano, Joseph Culotti, Satoshi Suo, William S. Ryu, Suneil K. Kalia, Lorraine V. Kalia
Format: article
Langue:EN
Publié: BMC 2021
Sujets:
Alpha-synuclein
Animal model
Artificial intelligence
Drug discovery
Machine learning
Natural language processing
Neurology. Diseases of the nervous system
RC346-429
Geriatrics
RC952-954.6
Accès en ligne:https://doaj.org/article/1a816ab50aad45a9bf006d7c91b18cff
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/1a816ab50aad45a9bf006d7c91b18cff

Documents similaires